Literature DB >> 12373012

Mechanisms of steroid impairment of growth.

Ze'ev Hochberg1.   

Abstract

With child growth being multifactorial and the glucocorticoids (GC) having many target physiological and biochemical mechanisms, growth and the GC collide in several meeting points. Indirectly, GC have a general anti-anabolic and catabolic influences that include bone, cartilage and muscle proteins. The GC interfere with the GH-IGF-1 axis at the hypothalamic, pituitary and target organ levels, affecting hormone release, receptor abundance, signal transduction, gene transcription, pre-mRNA splicing and mRNA translation. GC disturb normal calcium balance at the intestine and kidney. Direct effects at the growth plate include the suppression of multiple gene expression, chondrocyte proliferation and matrix proteoglycan synthesis, sulfation, release and mineralization as well as the augmentation of hypertrophic cell apoptosis. At the tissues adjacent to the growth plate, GC enhance osteoclast and suppress osteoblast recruitment and function, they reduce muscle strength and disrupt the normal control of vascular invasion at the cartilage-bone interface. Growth damage from GC is maximal during the initial months of treatment and prevention is more effective than post-factual therapy. To reduce these growth-retarding effects, the following measures, which are partly experimental, may be effective in a decreasing order: minimize GC dose and use an alternate-day treatment; utilize the oxazoline analog of prednisolone deflazacort, normalize calcium balance; employ hGH or IGF-1. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373012     DOI: 10.1159/000064764

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  33 in total

1.  Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats.

Authors:  R H Nielsen; C Christiansen; M Stolina; M A Karsdal
Journal:  Clin Exp Immunol       Date:  2008-01-28       Impact factor: 4.330

2.  Growth hormone response to physical exercise in growing patients with classic congenital adrenal hyperplasia.

Authors:  C Bizzarri; G Ubertini; F Crea; D Colabianchi; S Loche; L Ravà; M Cappa
Journal:  J Endocrinol Invest       Date:  2009-06-24       Impact factor: 4.256

3.  Optimizing Stature in Congenital Adrenal Hyperplasia: Challenges and Solutions.

Authors:  Anju Seth
Journal:  Indian J Pediatr       Date:  2019-04-27       Impact factor: 1.967

Review 4.  Cancer therapies and bone health.

Authors:  Mimi I Hu; Huifang Lu; Robert F Gagel
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

5.  Bone density in post-pubertal adolescent survivors of childhood brain tumors.

Authors:  Laurie E Cohen; Joshua H Gordon; Erica Y Popovsky; Nina N Sainath; Henry A Feldman; Mark W Kieran; Catherine M Gordon
Journal:  Pediatr Blood Cancer       Date:  2011-08-29       Impact factor: 3.167

Review 6.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

7.  The growth hormone receptor (GHR) polymorphism in growth-retarded children with Cushing disease: lack of association with growth and measures of the somatotropic axis.

Authors:  L Drori-Herishanu; M Lodish; S Verma; E Bimpaki; M F Keil; A Horvath; C A Stratakis
Journal:  Horm Metab Res       Date:  2009-12-09       Impact factor: 2.936

8.  Association of insulin-like growth factor-1 with thyroid nodules.

Authors:  Ying-Jian Liu; Wei Qiang; Xing-Jun Liu; Li Xu; Hui Guo; Li-Ping Wu; Bingyin Shi
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

9.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

10.  The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model.

Authors:  Jason M Sansone; Norman J Wilsman; Ellen M Leiferman; James Conway; Paul Hutson; Kenneth J Noonan
Journal:  J Pediatr Orthop       Date:  2009-03       Impact factor: 2.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.